Advertisement

 

 

The microbiome and HIV prevention strategies in women.

The microbiome and HIV prevention strategies in women.
Author Information (click to view)

Abdool Karim SS, Passmore JS, Baxter C,


Abdool Karim SS, Passmore JS, Baxter C, (click to view)

Abdool Karim SS, Passmore JS, Baxter C,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Current opinion in HIV and AIDS 2017 10 20() doi 10.1097/COH.0000000000000431

Abstract
PURPOSE OF REVIEW
HIV prevention approaches that women can use and control are a priority. Results from topical and oral preexposure prophylaxis (PrEP) HIV prevention trials have produced inconsistent results in women. One of the main behavioural factors impacting effectiveness of PrEP has been suboptimal adherence. In this review, we examine biological factors that modulate topical PrEP efficacy, with particular focus on the vaginal microbiome.

RECENT FINDINGS
Genital inflammation is an independent risk factor for HIV acquisition in women. Using 16S rRNA sequencing of the vaginal microbiota, anaerobic bacteria linked with bacterial vaginosis have been shown to be associated with both genital inflammation and HIV risk. Using proteomics, it was recently discovered that a dysbiotic vaginal microbiome, comprising less than 50% Lactobacillus spp., directly influenced topical PrEP efficacy. Gardnerella vaginalis, the dominant vaginal species in dysbiotic women, was able to directly degrade tenofovir, but not dapivirine, an antiretroviral also being developed for topical PrEP.

SUMMARY
The link between bacterial vaginosis-associated organisms with HIV risk and altered tenofovir gel effectiveness underscores the importance of good vaginal health and good adherence for women to benefit maximally from topical PrEP. Altering the vaginal microbiome is one of the new directions being pursued for HIV prevention.

Submit a Comment

Your email address will not be published. Required fields are marked *

twenty + two =

[ HIDE/SHOW ]